IMPAVIDO (Profounda, Inc.)


Welcome to the PulseAid listing for the IMPAVIDO drug offered from Profounda, Inc.. This Antileishmanial [EPC] pharmaceutical is classified as a HUMAN PRESCRIPTION DRUG. Below, you can view details for this drug, such as its dosage form, route of delivery, start market/end market dates, and more. We have also randomly listed additional pharmaceuticals used in the same HUMAN PRESCRIPTION DRUG drug type category.
LABELER NAME / MANUFACTURER: Profounda, Inc.
NON-PROPRIETARY NAME: miltefosine
SUBSTANCE NAME: MILTEFOSINE
TYPE: HUMAN PRESCRIPTION DRUG
PHARMA CLASS: Antileishmanial [EPC]
ROUTE: ORAL
DOSAGE FORM: CAPSULE
MARKETING CATEGORY NAME: NDA
START MARKETING DATE: 2015-10-29
END MARKETING DATE: 0000-00-00


IMPAVIDO HUMAN PRESCRIPTION DRUG Details:

Item DescriptionIMPAVIDO from Profounda, Inc.
LABELER NAME: Profounda, Inc.
DEA SCHEDULE:
ACTIVE STRENGTH: 50(mg/1)
START MARKETING DATE: 2015-10-29
END MARKETING DATE: 0000-00-00
PRODUCT ID: 69051-300_bcb387ac-2e90-4f5e-94b2-d3635190678e
PRODUCT NDC: 69051-300
APPLICATION NUMBER: NDA204684

Other MILTEFOSINE Pharmaceutical Manufacturers / Labelers:

Manufacturer / LabelerProprietary Name
Paladin Therapeutics Inc.IMPAVIDO
Profounda, Inc.IMPAVIDO